Ankur Drugs & Pharma Ltd - Stock Valuation and Financial Performance

Name: Ankur Drugs & Pharma
Brand: Ankur Drugs & Pharma

BSE: 531683 | NSE: ANKURDRUGS | Pharmaceuticals & Drugs | Small Cap

Place order

BSE Share Price
Not Listed

DeciZen - make an informed investing decision on Ankur Drugs & Pharma

Based on:

Data

M-Cap below 100cr DeciZen not available

Ankur Drugs & Pharma stock performance -

PE Chart Key Ratios

P/E Ratio (SA):

0.00

Market Cap:

7.6 Cr.

52-wk low:

3.7

52-wk high:

Is an attractive stock to invest in?

1. Is a good quality company?

Data is not available for this company.

2. Is undervalued or overvalued?

No data found

3. Is a good buy now?

No data found

10 Year X-Ray of Ankur Drugs & Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'03	Mar'04	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	TTM
ROCE % ⓘ	6.2%	16.2%	14.9%	16.5%	13.8%	12.4%	10.2%	11.3%	1.2%	-11.2%	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	18.3	54.9	78.6	136	373	674	965	1,067	825	151	142
Sales YoY Gr.	-	200.5%	43.1%	73.6%	173.5%	80.5%	43.3%	10.6%	-22.7%	-81.6%	-
Adj EPS ⓘ	0.9	4	5.2	14.7	31	50	30.3	38.6	-35.1	-106.8	-127.9
YoY Gr.	-	325.5%	30.8%	181.6%	110.5%	61.2%	-39.4%	27.3%	-191.1%	NA	-
BVPS (₹) ⓘ	10.8	12.9	17	30.1	99.2	165.5	140.4	164	126.6	-29.8	-95.9
Adj Net Profit ⓘ	0.9	3.8	5	14	32.7	63.5	56.4	74.6	-67.9	-206	-247
Cash Flow from Ops. ⓘ	-1	3.4	5	7.6	22.9	21.5	41.9	844	-40.5	3.2	-
Debt/CF from Ops. ⓘ	-14.9	7.9	9.5	14.7	15.4	28.8	17.8	1.1	-30.1	309	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	26.5%	-16.5%	-46.1%	-81.6%
Adj EPS ⓘ	-269.2%	-228.1%	-252.2%	NA
BVPSⓘ	-212%	-178.6%	-159.7%	-123.6%
Share Price	-	-	-	-

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'03	Mar'04	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12	TTM
Return on Equity % ⓘ	8.7	32.6	34.1	61.8	46.1	38.2	23	23.7	-21	-78.4	203.4
Op. Profit Mgn % ⓘ	18.2	18.4	16.7	16.1	15.5	15.9	16.4	19.6	16.4	-16.4	-25.2
Net Profit Mgn % ⓘ	4.7	6.9	6.3	10.3	8.8	9.4	5.8	7	-8.2	-136.3	-173.6
Debt to Equity ⓘ	1.5	2.2	3	3.9	3.4	2.9	2.9	3	5	-17.1	-
Working Cap Days ⓘ	93	85	108	107	97	120	151	142	124	348	109
Cash Conv. Cycle ⓘ	50	60	87	89	76	98	128	32	-34	102	-421

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Ankur Drugs & Pharma Ltd.

	Standalone	Consolidated
TTM EPS (₹)	-127.9	-
TTM Sales (₹ Cr.)	142	-
BVPS (₹.) ⓘ	-95.9	-
Reserves (₹ Cr.) ⓘ	-166	-
P/BV ⓘ	-0.04	-
PE ⓘ	0.00	-

From the Market
52 Week Low / High (₹)	3.65 / 4.02
All Time Low / High (₹)	1.75 / 486.90
Market Cap (₹ Cr.)	7.6
Equity (₹ Cr.)	19.3
Face Value (₹)	10
Industry PE ⓘ	47.9

Management X-Ray of Ankur Drugs & Pharma:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

59.41

79.60

76.77

72.58

71.65

69.92

57.87

47.63

12.36

14.99

* Pledged shares as % of Promoter's holding (%)

Valuation of Ankur Drugs & Pharma

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Ankur Drugs & Pharma

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'03	Mar'04	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12
Sales	18.28	54.93	78.58	136.45	373.24	673.50	965.32	1,067.41	824.85	151.49
Operating Expenses ⓘ	14.94	44.81	65.44	114.53	315.27	566.65	834.57	858.65	690.95	184.23
Manufacturing Costs	2.86	9.28	13.91	26.79	66.02	111.60	120.62	125.83	37.90	27.87
Material Costs	10.37	34.33	49.26	84.92	245.70	448.51	641.12	697.61	616.42	113.19
Employee Cost	0.94	0.22	0.23	0.23	0.59	1.36	12.24	15.80	20.44	18.80
Other Costs ⓘ	0.77	0.98	2.04	2.59	2.96	5.18	60.59	19.42	16.19	24.37
Operating Profit ⓘ	3.33	10.12	13.14	21.92	57.97	106.85	130.75	208.76	133.90	-32.74
Operating Profit Margin (%)	18.2%	18.4%	16.7%	16.1%	15.5%	15.9%	13.5%	19.6%	16.2%	-21.6%
Other Income ⓘ	0.01	0.28	0.04	0.14	0.49	1.51	2.94	18.63	0.93	17.54
Interest ⓘ	0.79	2.03	3.92	4.08	12.92	24.93	54.10	80.75	120.80	75.71
Depreciation ⓘ	0.96	1.04	2.02	2.50	6.02	8.40	20.67	26.64	60.80	61.19
Exceptional Items ⓘ	0	-1	0	0	0	0	0	0	0	-136.37
Profit Before Tax ⓘ	1.59	6.33	7.24	15.48	39.52	75.02	58.92	120	-46.77	-288.47
Tax ⓘ	0.73	3.23	2.27	1.51	6.79	11.51	21.79	33.82	22.04	19.02
Profit After Tax	0.86	3.10	4.97	13.98	32.73	63.50	37.13	86.18	-68.81	-307.49
PAT Margin (%)	4.7%	5.6%	6.3%	10.2%	8.8%	9.4%	3.8%	8.1%	-8.3%	-203.0%
Adjusted EPS (₹)	0.9	3.3	5.2	14.7	31.0	50.0	19.9	44.6	-35.6	-159.0
Dividend Payout Ratio (%)	0%	31%	19%	10%	6%	5%	11%	5%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'03	Mar'04	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12
Equity and Liabilities
Shareholders Fund	10.21	12.64	16.46	28.82	105.08	210.74	261.63	357.28	288.47	-19.02
Share Capital ⓘ	9.08	9.50	9.50	9.50	10.56	12.70	18.62	19.34	19.34	19.34
Reserves ⓘ	1.12	3.14	6.96	19.32	94.53	198.04	243.01	337.94	269.13	-38.36
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	14.31	26.78	47.80	111.32	351.79	618.14	744.70	950.41	980.38	712.12
Long Term Debt	14.31	26.78	47.80	111.32	351.79	618.14	744.70	950.41	458.96	598.28
Short Term Debt	0	0	0	0	0	0	0	0	521.42	113.84
Trade Payables	1.78	3.53	2.27	5.41	25.25	27.15	57.42	450.72	131.86	136.56
Others Liabilities ⓘ	1.28	5.37	7.80	10.92	23.06	43.89	70.79	114.95	378.77	698.99
Total Liabilities ⓘ	27.58	48.32	74.33	156.47	505.18	899.92	1,134.53	1,873.37	1,779.48	1,528.65
Fixed Assets
Gross Block	21.42	24.55	38.77	41.14	127.96	228.04	390.65	775.47	1,351.40	1,351.26
Accumulated Depreciation	2.59	3.63	5.66	8.16	15.58	23.89	44.50	71.07	131.54	192.57
Net Fixed Assetsⓘ	18.82	20.92	33.12	32.99	112.38	204.16	346.15	704.41	1,219.86	1,158.69
CWIP ⓘ	0	6.46	8.68	65.61	245.03	331.49	266.10	785.88	284.97	266.48
Investmentsⓘ	0	0.01	0.01	0.01	0.02	5.24	3.74	0.36	0.10	0.10
Inventories	3.71	11.10	14.48	24.56	62.18	123.15	212.77	260.85	165.36	17.69
Trade Receivables	4.27	8.40	15.31	28.35	76.90	163.91	281.14	54.85	38.17	31.76
Cash Equivalents	0.11	0.40	0.75	1.74	2.56	59.06	15.84	9.43	3.07	2.16
Others Assetsⓘ	0.65	1.04	1.98	3.21	6.11	12.92	8.79	57.59	67.96	51.78
Total Assets ⓘ	27.58	48.32	74.33	156.47	505.18	899.92	1,134.53	1,873.37	1,779.48	1,528.65

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'03	Mar'04	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12
Cash Flow From Operating Activity ⓘ	-0.96	3.38	5.01	7.57	22.86	21.50	41.87	843.72	-40.54	3.20
PBT ⓘ	1.61	7.30	7.28	15.41	39.36	75	58.92	120	-46.77	-288.47
Adjustment ⓘ	0.99	2.90	5.92	6.68	18.82	32.09	120.58	92.51	181.92	268.52
Changes in Working Capital ⓘ	-3.56	-3.8	-3.65	-9.72	-19.38	-51.28	-78	731.27	-170.65	24.46
Tax Paid ⓘ	0	0	-0.62	-0.72	-3.02	-9.38	-5.53	-19.31	-5.04	-1.30
Cash Flow From Investing Activity ⓘ	-0.96	-9.34	-16.40	-59.28	-187.75	-190.75	-94.27	-938.33	-91.53	23.96
Capex	-1.06	-3.13	-16.44	-59.34	-188.04	-186.53	-97.25	-904.75	-76.72	8.13
Net Investments	0.10	-0.01	0	0	-0.01	-5.22	0.08	4.74	0.28	0
Others ⓘ	0.01	-6.21	0.04	0.06	0.30	1	2.91	-38.32	-15.09	15.84
Cash Flow From Financing Activityⓘ	1.98	6.26	11.74	52.69	165.17	225.75	9.18	88.21	130.15	-26.92
Net Proceeds from Shares ⓘ	0.76	0	0	0	18.36	47.81	20.07	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	0	0	0	0	0	0	0	0	-109.83	-16.54
Dividend Paid ⓘ	0	0	-0.95	-0.95	-1.43	-2.54	-4.19	-4.28	-4.35	0
Others ⓘ	1.22	6.26	12.69	53.64	148.23	180.48	-6.70	92.49	244.32	-10.38
Net Cash Flow ⓘ	0.07	0.29	0.35	0.99	0.27	56.50	-43.22	-6.41	-1.92	0.25

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'03	Mar'04	Mar'05	Mar'06	Mar'07	Mar'08	Mar'09	Mar'10	Mar'11	Mar'12
Ratios
ROE (%)	9.38	28.07	34.93	62.51	49.12	40.33	15.75	29.79	-24.48	N/A
ROCE (%)	10.71	26.3	21.67	19.2	17.35	15.36	12.2	17.58	5.42	N/A
Asset Turnover Ratio	0.84	1.61	1.43	1.29	1.14	0.96	0.95	0.71	0.45	0.09
PAT to CFO Conversion(x)	-1.12	1.09	1.01	0.54	0.7	0.34	1.13	9.79	N/A	N/A
Working Capital Days
Receivable Days	43	38	49	53	51	65	84	57	20	84
Inventory Days	40	44	53	48	42	50	63	81	94	219
Payable Days	49	28	21	16	23	21	24	133	172	433

Ankur Drugs & Pharma Ltd Stock News

Ankur Drugs & Pharma Ltd FAQs

What is the share price of Ankur Drugs & Pharma?

Company share prices are keep on changing according to the market conditions. The closing price of Ankur Drugs & Pharma on 01-Jan-1970 05:30 is ₹0.00.

What is the market cap of Ankur Drugs & Pharma?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jan-1970 05:30 the market cap of Ankur Drugs & Pharma stood at ₹7.60.

What is the P/E ratio of Ankur Drugs & Pharma?

The latest P/E ratio of Ankur Drugs & Pharma as of 01-Jan-1970 05:30 is 0.00.

What is the P/B ratio of Ankur Drugs & Pharma?

The latest P/B ratio of Ankur Drugs & Pharma as of 01-Jan-1970 05:30 is -0.04.

What is the 52-week high and low of Ankur Drugs & Pharma?

The 52-week high of Ankur Drugs & Pharma is ₹4.02 and the 52-week low is ₹3.65.

What is the TTM revenue of Ankur Drugs & Pharma?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Ankur Drugs & Pharma is ₹142.5 ( Cr.) .

About Ankur Drugs & Pharma Ltd

Ankur Drugs and Pharma, formerly the Mridol Pharmaceuticals Limited was incorporated on February 9, 1995 with the Registrar of Companies, Maharashtra at Mumbai and a certificate of commencement of business was obtained on 7 March 1995. The Company was promoted by Shri Sandeep Parwal and Shri Harinarayan Attal. The company came up with a Public Issue of 57,00,000 Equity shares of Rs.10 each for cash at par opened for subscription in 1996 and the issue was oversubscribed.

The name of the company was changed from Mridol Pharmaceuticals Limited to Ankur Drugs and Pharma Limited in 1998.

Currently Ankur manufactures 400 different formulations for different dosage forms - viz Tablets, Capsules, Dry syrups, Liquid Orals,etc. Right from inception, Ankur has remained focused on its core business of Contract manufacturing. Since the last six years the company has not diluted itâ€™s equity base. Ankur's debt level appears high primarily because of â€œExpansion for Growthâ€. Ankur has used its debts mostly to fund the core business expansion at Baddi by creating production facility for â€œbest in worldâ€. Currently company operates in the ratio of 40% Loan License and 60% Third Party which it proposes to be 50:50 in coming future. Looking at the current business model companyâ€™s basic strategy is to approach big domestic players for contract manufacturing in formulations and maintain a sustainable net margin of 10% in their overall business. The company is targeting to grow multifold in coming years through contract manufacturing.

The company has recently announced that it will invest in the entire paid up share capital of TVC Life Sciences Ltd. in order to make it its wholly owned subsidiary. The group is engaged in manufacturing of pharma formulation in various dosage forms for leading Indian Companies. It is into 100% Contract Manufacturing activity and the plants are strategically located offering varied financial advantages to its customers.

Products:

ADPL is currently manufacturing brands like Mox, Cifran, Sporidex, Romilast, Fenak Plus, Omesec-20, Stanhist, Secafe, etc

Clientele:

Ranbaxy Laboratories Limited
Cipla Limited
Khandelwal Laboratories Pvt. Limited
Makers Laboratories Limited
Hetero Healthcare Limited
Elder Pharma Limited
Lyka Labs Limited
Blue Cross Laboratories Limited
Cadila Laboratories Limited
Wockhardt Limited
Glenmark Pharma Limited
Parentral Drugs (India) Limited
Torrent Pharmaceuticals Limited
Sandoz (India) pvt Limited
Shreya Life Sicences Pvt. Limited
Synthiko Formulations
Nicholas Piramal India Limited

The company is planning for various international approvals mainly the US FDA and EU MHRA for the Baddi Plant which would help the company to start export business.